Phase II
The fifth annual CAR-TCR Summit will kick off in Boston Tuesday with a focus on advancements in immunotherapies targeting various cancers, as well as challenges that face the field.
Neurotrope announced that its Phase II trial of Bryostatin-1 in moderate to severe Alzheimer’s disease did not show statistical significance on the primary endpoint, change from baseline to Week 13 in the Severe Impairment Battery (SIB) total score.
When Eli Lilly and Company acquired Loxo Oncology for $8 billion, the company was gambling on several pipeline drugs in oncology.
Ultragenyx Pharmaceutical Inc. announced positive data from the second dose cohort of the ongoing Phase 1/2 study of DTX401, an adeno-associated virus based gene therapy for the treatment of glycogen storage disease type Ia.
Apogenix announced that a new publication in Cancer Management and Research[1] reviews asunercept as a promising treatment option for patients with other malignancies beyond glioblastoma and myelodysplastic syndromes.
Hutchison China MediTech Limited has initiated an international Phase I/Ib study of HMPL-689, its novel, highly selective and potent small molecule phosphoinositide-3 kinase delta isoform inhibitor, in patients with relapsed or refractory lymphoma.
Akari Therapeutics, Plc announced financial results for the second quarter ended June 30, 2019 and recent clinical progress.
Esperion announced positive top-line results from the Phase 2 bempedoic acid / ezetimibe combination tablet study.
Santhera Pharmaceuticals announces publication by ReveraGen of positive study data with vamorolone in patients with Duchenne muscular dystrophy.
Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week.
PRESS RELEASES